Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Incyte initiates phase I study of INCB-099280 in solid tumors

Sep. 8, 2020

FluoGuide obtains Danish clearance for phase I/II trial of FG-001 to guide glioma surgery

Sep. 7, 2020

New FGFR-4 inhibitors presented by BridGene Biosciences

Sep. 7, 2020

Bristol-Myers Squibb discovers farnesoid X receptor agonists

Sep. 7, 2020

Denali Therapeutics identifies new EIF2B activators

Sep. 7, 2020

FDA grants accelerated approval to Gavreto for metastatic RET fusion-positive NSCLC

Sep. 7, 2020

First participant dosed in phase I study of SRN-14/GL2-800, a novel nucleic acid drug

Sep. 7, 2020

Relay begins first-in-human evaluation of FGFR2 inhibitor RLY-4008

Sep. 4, 2020

Enrollment opens in phase I study of LY-3410738 in advanced solid tumors with IDH1 mutations

Sep. 4, 2020

New phase I/II trial evaluates Treadwell's CFI-402411 in solid tumors

Sep. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...